Related references
Note: Only part of the references are listed.Mode of Action, In Vitro Activity, and In Vivo Efficacy of AFN-1252, a Selective Antistaphylococcal FabI Inhibitor
Nachum Kaplan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
AFN-1252, a FabI Inhibitor, Demonstrates a Staphylococcus-Specific Spectrum of Activity
James A. Karlowsky et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Inhibitors of Fabl, an enzyme drug target in the bacterial fatty acid biosynthesis pathway
Hao Lu et al.
ACCOUNTS OF CHEMICAL RESEARCH (2008)
In vitro activity of API-1252, a novel FabI inhibitor, against clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis
James A. Karlowsky et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Inhibiting bacterial fatty acid synthesis
Yong-Mei Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Inhibition of daptomycin by pulmonary surfactant: In vitro modeling and clinical impact
JA Silverman et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Assessing in vitro combinations of antifungal drugs against yeasts and filamentous fungi:: comparison of different drug interaction models
J Meletiadis et al.
MEDICAL MYCOLOGY (2005)
Structure and molecular organization of mammalian fatty acid synthase
FJ Asturias et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2005)
Determination of selectivity and efficacy of fatty acid synthesis inhibitors
S Kodali et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI)
WH Miller et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
Inhibitors of fatty acid synthesis as antimicrobial chemotherapeutics
RJ Heath et al.
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY (2002)
Share Paper
